EXCLUSION CRITERIA: 1. Patients with vasodilatory shock, orthostatic hypotension, hypotension, or tachycardia atscreening or baseline 2. Patients experiencing cerebral hemorrhage or cerebral infarction at baseline3. Patients with galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption4. Patients taking drugs that increase risk of bleeding (e.g. anti-coagulants, anti-platelet)5. Patients taking droxidopa6. ALT/AST &gt, 5 times the upper limit of normal at baseline7. Stage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR &lt, 30) at baseline8. Presence of other disease that may interfere with testing procedures or which in the judgementof the Investigator may interfere with trial participation or may put the patient at risk whenparticipating in this trial9. Pregnant and lactating women and those planning to get pregnant10. Known or suspected allergy to the trial drug or the relevant drugs given in the trial11. Patients who have participated in any other clinical trial/s, including a COVID-19 trial, within thepast 3 months12. The participant is, in the opinion of the PI, unlikely to comply with the clinical study protocol oris unsuitable for any other reason

EXCLUSION CRITERIA: 1. Patients with vasodilatory shock, orthostatic hypotension, hypotension, or tachycardia atscreening or baseline 2. Patients experiencing cerebral hemorrhage or cerebral infarction at baseline3. Patients with galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption4. Patients taking drugs that increase risk of bleeding (e.g. anti-coagulants, anti-platelet)5. Patients taking droxidopa6. ALT/AST &gt, 5 times the upper limit of normal at baseline7. Stage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR &lt, 30) at baseline8. Presence of other disease that may interfere with testing procedures or which in the judgementof the Investigator may interfere with trial participation or may put the patient at risk whenparticipating in this trial9. Pregnant and lactating women and those planning to get pregnant10. Known or suspected allergy to the trial drug or the relevant drugs given in the trial11. Patients who have participated in any other clinical trial/s, including a COVID-19 trial, within thepast 3 months12. The participant is, in the opinion of the PI, unlikely to comply with the clinical study protocol oris unsuitable for any other reason